Justin Petrone covers consumer genomics, ancestry testing, and the microarray and biochip sector of the genomics market for GenomeWeb.
Consumer genomics companies have endeavored to reach out to minority communities with sometimes contentious results.
The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.
The projects, set to begin this year, concern prostate cancer, infectious diseases, rheumatoid arthritis, inflammatory bowel disease, heart disease, and sleep disorders.
The effort, outlined in a Development Cell paper published online today, aims to complement the ongoing Human Cell Atlas initiative, but with a focus on pediatric health.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
The alliance has also deepened its ongoing partnership with ELIXIR, while continuing to roll out new tools and standards for genomic data discovery, analysis, and interpretation.
The revelation that Family Tree DNA has been working with law enforcement has some worried about a negative impact on the industry.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.